ArticleCancer medicine2024

Real-world analysis of adverse event rates after initiation of ibrutinib among Medicare beneficiaries with chronic lymphocytic leukemia.

Scott F Huntington et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.